Breast CancerSan Antonio 2022 Update of the monarchE trial with abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer 9 December 2022 The 4-year follow up data of a pre-planned overall survival analysis of the...